Showing results (161-170 of 389) with videos related to

Sort By:
Pageof 39
Oncotarget|December 5, 2014
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cellsHisato Kawakami, Isamu Okamoto, Kimio Yonesaka, et al.
Microbiology Spectrum|February 1, 2023
Respiratory Virus Infections during the COVID-19 Pandemic Revealed by Multiplex PCR Testing in JapanSho Yamashita, Satoshi Ikegame, Keita Nakatomi, et al.
Frontiers in Immunology|July 13, 2023
Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1βAiko Hirayama, Kentaro Tanaka, Hirono Tsutsumi, et al.
Cancer Science|May 20, 2020
Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosisKohei Otsubo, Eiji Iwama, Kayo Ijichi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancerVera Hirsh, Isamu Okamoto, Jeremy K Hon, et al.
Investigational New Drugs|December 16, 2014
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumorsYasuhito Fujisaka, Takayasu Kurata, Kaoru Tanaka, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 2021
Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinibRenpeng Liu, Keiichi Ota, Eiji Iwama, et al.
Clinical Lung Cancer|November 22, 2021
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)Yoshimasa Shiraishi, Taiki Hakozaki, Shogo Nomura, et al.
Plos One|February 7, 2022
The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitorsKazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, et al.
JMA Journal|August 22, 2022
Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung CancerRintaro On, Takemasa Matsumoto, Noriyuki Ebi, et al.
Pageof 39